A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Stopped early · Phase 1/Phase 2

Conditions studied: Pemphigus, Pemphigus Vulgaris, Pemphigus Foliaceus

In brief

This was a multicenter, open-label safety study to determine the dose regimen of SYNT001 (ALXN1830) administered intravenously in participants with pemphigus (vulgaris or foliaceus).

Key facts

Study ID
NCT03075904
Run by
Alexion Pharmaceuticals, Inc.
People needed
8
Starts
2017-07-18
Expected to finish
2019-01-16
Last updated by the study team
2020-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.